524 related articles for article (PubMed ID: 24029138)
1. Clinical sequelae after rhBMP-2 use in a minimally invasive transforaminal lumbar interbody fusion.
Singh K; Nandyala SV; Marquez-Lara A; Cha TD; Khan SN; Fineberg SJ; Pelton MA
Spine J; 2013 Sep; 13(9):1118-25. PubMed ID: 24029138
[TBL] [Abstract][Full Text] [Related]
2. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease--part 2: BMP dosage-related complications and long-term outcomes in 509 patients.
Crandall DG; Revella J; Patterson J; Huish E; Chang M; McLemore R
Spine (Phila Pa 1976); 2013 Jun; 38(13):1137-45. PubMed ID: 23354111
[TBL] [Abstract][Full Text] [Related]
3. Promoting fusion in minimally invasive lumbar interbody stabilization with low-dose bone morphogenic protein-2--but what is the cost?
Mannion RJ; Nowitzke AM; Wood MJ
Spine J; 2011 Jun; 11(6):527-33. PubMed ID: 20739225
[TBL] [Abstract][Full Text] [Related]
4. Comparison of transforaminal lumbar interbody fusion outcomes in patients receiving rhBMP-2 versus autograft.
Khan TR; Pearce KR; McAnany SJ; Peters CM; Gupta MC; Zebala LP
Spine J; 2018 Mar; 18(3):439-446. PubMed ID: 28822825
[TBL] [Abstract][Full Text] [Related]
5. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease--part 1: Large series diagnosis related outcomes and complications with 2- to 9-year follow-up.
Crandall DG; Revella J; Patterson J; Huish E; Chang M; McLemore R
Spine (Phila Pa 1976); 2013 Jun; 38(13):1128-36. PubMed ID: 23370679
[TBL] [Abstract][Full Text] [Related]
6. Complications of rhBMP-2 utilization for posterolateral lumbar fusions requiring reoperation: a single practice, retrospective case series report.
Hoffmann MF; Jones CB; Sietsema DL
Spine J; 2013 Oct; 13(10):1244-52. PubMed ID: 23973099
[TBL] [Abstract][Full Text] [Related]
7. Symptomatic ectopic bone formation after off-label use of recombinant human bone morphogenetic protein-2 in transforaminal lumbar interbody fusion.
Chen NF; Smith ZA; Stiner E; Armin S; Sheikh H; Khoo LT
J Neurosurg Spine; 2010 Jan; 12(1):40-6. PubMed ID: 20043763
[TBL] [Abstract][Full Text] [Related]
8. Prospective, randomized, controlled trial of silicate-substituted calcium phosphate versus rhBMP-2 in a minimally invasive transforaminal lumbar interbody fusion.
Nandyala SV; Marquez-Lara A; Fineberg SJ; Pelton M; Singh K
Spine (Phila Pa 1976); 2014 Feb; 39(3):185-91. PubMed ID: 24253788
[TBL] [Abstract][Full Text] [Related]
9. Vertebral osteolysis originating from subchondral cyst end plate defects in transforaminal lumbar interbody fusion using rhBMP-2. Report of two cases.
Balseiro S; Nottmeier EW
Spine J; 2010 Jul; 10(7):e6-e10. PubMed ID: 20488766
[TBL] [Abstract][Full Text] [Related]
10. Revision surgery after interbody fusion with rhBMP-2: a cautionary tale for spine surgeons.
Rodgers SD; Marascalchi BJ; Grobelny BT; Smith ML; Samadani U
J Neurosurg Spine; 2013 Jun; 18(6):582-7. PubMed ID: 23560709
[TBL] [Abstract][Full Text] [Related]
11. Minimally invasive transforaminal lumbar interbody fusion: one surgeon's learning curve.
Nandyala SV; Fineberg SJ; Pelton M; Singh K
Spine J; 2014 Aug; 14(8):1460-5. PubMed ID: 24290313
[TBL] [Abstract][Full Text] [Related]
12. RhBMP-2-induced radiculitis in patients undergoing transforaminal lumbar interbody fusion: relationship to dose.
Villavicencio AT; Burneikiene S
Spine J; 2016 Oct; 16(10):1208-1213. PubMed ID: 27343729
[TBL] [Abstract][Full Text] [Related]
13. Complications with recombinant human bone morphogenetic protein-2 in posterolateral spine fusion associated with a dural tear.
Glassman SD; Gum JL; Crawford CH; Shields CB; Carreon LY
Spine J; 2011 Jun; 11(6):522-6. PubMed ID: 20598649
[TBL] [Abstract][Full Text] [Related]
14. Complications associated with single-level transforaminal lumbar interbody fusion.
Rihn JA; Patel R; Makda J; Hong J; Anderson DG; Vaccaro AR; Hilibrand AS; Albert TJ
Spine J; 2009 Aug; 9(8):623-9. PubMed ID: 19482519
[TBL] [Abstract][Full Text] [Related]
15. Adjacent vertebral body osteolysis with bone morphogenetic protein use in transforaminal lumbar interbody fusion.
Helgeson MD; Lehman RA; Patzkowski JC; Dmitriev AE; Rosner MK; Mack AW
Spine J; 2011 Jun; 11(6):507-10. PubMed ID: 21729801
[TBL] [Abstract][Full Text] [Related]
16. Safety of transforaminal lumbar interbody fusion and intervertebral recombinant human bone morphogenetic protein-2.
Villavicencio AT; Burneikiene S; Nelson EL; Bulsara KR; Favors M; Thramann J
J Neurosurg Spine; 2005 Dec; 3(6):436-43. PubMed ID: 16381205
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of recombinant human bone morphogenetic protein-2 versus local bone graft in primary lumbar interbody fusions.
Adams CL; Ogden K; Robertson IK; Broadhurst S; Edis D
Spine (Phila Pa 1976); 2014 Jan; 39(2):164-71. PubMed ID: 24153173
[TBL] [Abstract][Full Text] [Related]
18. Nerve injury and recovery after lateral lumbar interbody fusion with and without bone morphogenetic protein-2 augmentation: a cohort-controlled study.
Lykissas MG; Aichmair A; Sama AA; Hughes AP; Lebl DR; Cammisa FP; Girardi FP
Spine J; 2014 Feb; 14(2):217-24. PubMed ID: 24269858
[TBL] [Abstract][Full Text] [Related]
19. Neuroforaminal chondrocyte metaplasia and clustering associated with recombinant bone morphogenetic protein-2 usage in transforaminal lumbar interbody fusion.
Christensen TJ; Annis P; Hohl JB; Patel AA
Spine J; 2014 Jun; 14(6):e23-8. PubMed ID: 24291359
[TBL] [Abstract][Full Text] [Related]
20. Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2).
Wong DA; Kumar A; Jatana S; Ghiselli G; Wong K
Spine J; 2008; 8(6):1011-8. PubMed ID: 18037352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]